Nalini Singh, MD
Endocrinology, Diabetes & Metabolism · San Dimas, CANPI 1619070539
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $651 of the $727 with a category attached, or 89.5%. 10 manufacturers reported payments, led by Abbott at 30.4% of the total. 2025 is the largest year on record at $278, 8.6 times the $32 reported in 2020. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 32 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$221
- Novo Nordisk$151
- Organogenesis Inc.$125
- Insulet Corporation$104
- Orthofix Medical, Inc.$45
- Medtronic$26
- plus $54 from 4 others
What the payments were for
- Food & beverage$65190%
- Education$7610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $221 |
| Novo Nordisk | 6 | $151 |
| Organogenesis Inc. | 1 | $125 |
| Insulet Corporation | 6 | $104 |
| Orthofix Medical, Inc. | 1 | $45 |
| Medtronic | 1 | $26 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| RGH Enterprises LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$727 in reported general payments places this provider in the 40th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $170,641 |
| TrulicityDulaglutide | 83 | $115,259 |
| OzempicSemaglutide | 72 | $90,912 |
| Teriparatide | 24 | $63,551 |
| JardianceEmpagliflozin | 33 | $43,241 |
| JanuviaSitagliptin Phosphate | 37 | $42,634 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $28,075 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $24,917 |
| ProliaDenosumab | 12 | $20,650 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $20,285 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $17,606 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $16,222 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $15,635 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 75 | $9,596 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $8,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $12 | $288,755219 claims |
| Novo NordiskOzempic | $151 | $90,91272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Dimas
- Bashar SaadSan Dimas$123K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.